We are analyzing https://link.springer.com/article/10.1186/s13045-015-0194-5.

Title:
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer | Journal of Hematology & Oncology
Description:
Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy. This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, breast, palbociclib, article, combination, therapy, advanced, google, scholar, inhibitor, fulvestrant, study, pubmed, letrozole, patients, treatment, cdk, phase, hernegative, cas, research, women, hormonereceptorpositive, metastatic, postmenopausal, endocrine, inhibitors, trial, iii, abemaciclib, journal, access, prior, cell, disease, randomized, survival, paloma, oncol, asco, meeting, abstracts, privacy, cookies, positive, open, progressed, clinical, kinase, hrpositive,

Topics {✒️}

semi-mechanistic pharmacokinetic/pharmacodynamic modeling advanced hormone-receptor-positive her2-advanced breast cancer received anti-hormonal therapy her2-negative breast cancer hr-positive breast cancer longer progression-free survival median progression-free survival locally advanced er-positive cdk4-amplified human liposarcoma article download pdf initial endocrine-based therapy advanced breast cancer hormone-receptor-positive hormone receptor positive targeted therapy dose-dependent antitumor activity research highlight summarized estrogen receptor-positive her2-breast cancer metastatic breast cancer class cdk4/cdk6 inhibitor breast cancer res placebo-controlled study oestrogen receptor-positive open-label trial double-blind prior systemic therapy excellent alternative therapy cyclin-dependent kinase advanced hr-positive prior endocrine therapy privacy choices/manage cookies mol cancer ther clin cancer res creative commons license neoadjuvant trial investigating phase lb study cell cycle [7] cdk4/cdk6 inhibitors advanced cancer estrogen receptor her2-locoregionally recurrent neoadjuvant therapy settings paloma3 study concluded ph ib study small molecule inhibitors european economic area reduced cellular proliferation common adverse event

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
         description:Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy. This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.
         datePublished:2015-08-13T00:00:00Z
         dateModified:2015-08-13T00:00:00Z
         pageStart:1
         pageEnd:3
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13045-015-0194-5
         keywords:
            Breast cancer
            CDK4/CDK6 inhibitor
            Palbociclib
            Oncology
            Hematology
            Cancer Research
         image:
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Janice Lu
               affiliation:
                     name:David Geffen School of Medicine, University of California
                     address:
                        name:Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
      description:Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy. This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.
      datePublished:2015-08-13T00:00:00Z
      dateModified:2015-08-13T00:00:00Z
      pageStart:1
      pageEnd:3
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13045-015-0194-5
      keywords:
         Breast cancer
         CDK4/CDK6 inhibitor
         Palbociclib
         Oncology
         Hematology
         Cancer Research
      image:
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Janice Lu
            affiliation:
                  name:David Geffen School of Medicine, University of California
                  address:
                     name:Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:8
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:David Geffen School of Medicine, University of California
      address:
         name:Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Janice Lu
      affiliation:
            name:David Geffen School of Medicine, University of California
            address:
               name:Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA

External Links {🔗}(71)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.3s.

LINK . SPRINGER . COM {}